Apigenin and Heart Health: What the Research Says About Blood Pressure and Endothelial Function

Apigenin is a plant-derived flavonoid found in chamomile, parsley, celery, and several other common foods. Beyond its well-studied effects on sleep and anxiety, apigenin has attracted research attention for potential cardiovascular benefits—particularly around blood pressure regulation and the health of blood vessel linings. These are meaningful targets: endothelial dysfunction is considered an early, modifiable step in cardiovascular disease progression.

The research on apigenin and cardiovascular function is real but still developing. Most studies have been conducted in cell cultures or animal models, and large human clinical trials are limited. This article walks through what the current evidence shows, explains the proposed biological mechanisms in plain terms, and is honest about where the science is strong versus where significant gaps remain. These statements have not been evaluated by the FDA; apigenin is not intended to diagnose, treat, cure, or prevent any disease.

Why Blood Vessels Matter: A Brief Primer on Endothelial Function

The endothelium is the thin layer of cells lining every blood vessel in your body. It does far more than serve as a passive barrier—it actively regulates vascular tone, inflammation, platelet aggregation, and blood flow by releasing signaling molecules, most notably nitric oxide (NO). When endothelial function is impaired, vessels lose their ability to dilate appropriately, and chronic low-grade vascular inflammation can set in. This state, called endothelial dysfunction, is an early marker of cardiovascular risk and a contributing factor to elevated blood pressure.

Dietary polyphenols, including flavonoids like apigenin, have been studied as potential modulators of endothelial health. A 2015 review noted that dietary polyphenols can regulate endothelial function through multiple pathways, with nitric oxide bioavailability as a central mechanism ^[4]. Apigenin sits within this broader class of compounds, but it has several pharmacological properties that distinguish it from other flavonoids.

Apigenin and Nitric Oxide: The Vasodilation Pathway

Nitric oxide is produced by an enzyme called endothelial nitric oxide synthase (eNOS). When eNOS is activated, it generates NO, which diffuses into smooth muscle cells lining blood vessels and triggers relaxation—reducing vascular resistance and, in turn, blood pressure. Research has shown that apigenin can activate eNOS through calcium-dependent and phosphatidylinositol 3-kinase/Akt-dependent signaling pathways, leading to increased nitric oxide production in endothelial cells ^[2].

Earlier work confirmed that flavonoids as a class can stimulate nitric oxide synthase activity ^[1], and apigenin specifically has been examined in the context of resistance vessels—the small arteries most responsible for peripheral vascular resistance and blood pressure control. A 2024 study in hypertensive rats found that apigenin induced vasodilation in resistance vessels through both nitric oxide and calcium-activated potassium channel mechanisms, suggesting the effect involves more than one complementary pathway ^[11].

It is worth noting that some of the estrogen-like signaling observed with certain polyphenols may also play a role in eNOS activation. Research on wine-derived polyphenols showed estrogen receptor-mediated nitric oxide synthesis in human endothelial cells ^[3], a mechanism that may be relevant to apigenin given its known phytoestrogenic activity, though the practical significance in humans at typical dietary intakes remains uncertain.

Reversing Endothelial Aging: Evidence from Animal Studies

One of the more compelling preclinical studies on apigenin and vascular health examined aged mice given apigenin supplementation. The researchers found that apigenin restored endothelial function by reducing oxidative stress, reversed aortic stiffening (a key measure of large-artery aging), and reduced markers of vascular inflammation ^[6]. These are three distinct but interrelated aspects of cardiovascular aging, and the fact that a single compound appeared to address all three in the same model is noteworthy.

Aortic stiffness is clinically significant because it increases the workload on the heart and is independently associated with cardiovascular events. Oxidative stress damages the endothelium by reducing NO bioavailability—reactive oxygen species can quench nitric oxide before it reaches smooth muscle cells. Apigenin’s antioxidant capacity may therefore support NO signaling indirectly, in addition to its direct eNOS-activating effects ^[6].

These findings are promising but must be interpreted with caution. Animal models of vascular aging do not always translate directly to human outcomes. The doses used in animal studies are frequently higher than what a typical supplement provides, and the mechanistic pathways, while plausible, have not been confirmed in large human trials.

Flavonoids and Blood Pressure: Where Apigenin Fits

Apigenin does not exist in isolation—it belongs to a well-studied family of plant compounds with a recognized track record in hypertension research. A 2024 review of flavonoids and hypertension described multiple mechanisms through which this class of compounds may lower blood pressure, including ACE inhibition, calcium channel modulation, eNOS activation, and antioxidant effects ^[10]. Another review focused specifically on flavonoids from Chinese herbal medicine documented apigenin among the compounds with antihypertensive potential ^[7].

Celery is one of the richest dietary sources of apigenin, and a 2024 narrative review on celery’s antihypertensive properties highlighted its flavonoid content as a likely contributor to blood pressure effects observed in animal models ^[9]. A broader phytotherapy review similarly noted that plants rich in flavonoids like apigenin show antihypertensive activity in experimental settings ^[5].

A review of flavonoid effects in animal models of hypertension found evidence across multiple experimental paradigms for blood-pressure-lowering activity in this compound class ^[8]. Again, the consistent theme is promising preclinical data paired with a recognized need for more human clinical evidence before confident conclusions can be drawn.

Mitochondrial Health and Vascular Function: An Emerging Link

A newer area of cardiovascular research focuses on mitochondrial dysfunction as a driver of hypertension. Vascular smooth muscle cells and endothelial cells are energy-intensive and depend on healthy mitochondria for normal function. When mitochondrial efficiency declines, reactive oxygen species production increases, endothelial NO signaling is impaired, and vascular inflammation worsens. A 2026 mechanistic review described these mitochondrial pathways as therapeutically relevant targets in hypertension ^[12].

Apigenin has shown some ability to support mitochondrial function in cellular models, which could theoretically complement its direct vascular effects. However, the direct connection between apigenin’s mitochondrial activity and clinical blood pressure outcomes in humans has not been established. This remains a hypothesis worth watching as research matures.

Practical Considerations: Dietary Sources and Supplement Context

Apigenin is present in chamomile tea, parsley, celery, and to a lesser extent in many other fruits and vegetables. Chamomile tea is one of the most convenient and widely consumed sources. Supplemental apigenin is also available, typically in capsule form at doses ranging from 50 mg to 500 mg per day, though no established therapeutic dose has been confirmed for cardiovascular endpoints in human trials.

Anyone considering apigenin supplementation for cardiovascular reasons should be aware of several drug interactions. Apigenin inhibits cytochrome P450 enzymes CYP1A2, CYP2C9, and CYP3A4. This means it can alter the metabolism of medications processed by these pathways—including warfarin, certain statins, and some calcium channel blockers. Individuals taking blood pressure medications, anticoagulants, or other cardiovascular drugs should consult their prescribing physician before adding apigenin supplements. Apigenin also has sedative properties through GABA-A receptor binding, so stacking with other sedatives, alcohol, or benzodiazepines warrants caution.

A Note on the Evidence

Most evidence for apigenin’s cardiovascular effects comes from cell and animal studies; human clinical trial data is limited, so claims about blood pressure benefits in people should be understood as preliminary. Apigenin inhibits CYP1A2, CYP2C9, and CYP3A4 and may interact with warfarin, statins, calcium channel blockers, and benzodiazepines—individuals on any prescription cardiovascular or anticoagulant medication should consult their physician before use. These statements have not been evaluated by the FDA; apigenin is not intended to diagnose, treat, cure, or prevent any disease.

Frequently Asked Questions

How does apigenin affect blood pressure mechanistically?

Apigenin appears to work through several pathways simultaneously. It activates eNOS via calcium and PI3K/Akt signaling to increase nitric oxide production, which relaxes vascular smooth muscle ^[2]. It also activates calcium-sensitive potassium channels in resistance vessels, contributing to vasodilation in hypertensive animal models ^[11]. Antioxidant activity may further protect nitric oxide from degradation by reactive oxygen species.

Is there human clinical trial evidence for apigenin and blood pressure?

Current evidence is predominantly from cell culture and animal studies. Reviews of flavonoids and hypertension identify apigenin as a promising compound with mechanistic support [PMID 38616386, PMID 34601080], but large, well-controlled human randomized trials specifically testing apigenin for blood pressure are lacking. Dietary celery, a rich source of apigenin, has been reviewed for antihypertensive effects ^[9], but isolating apigenin’s contribution from other compounds in whole foods is difficult.

What does 'endothelial function' mean and why does it matter for heart health?

The endothelium is the inner lining of blood vessels. When healthy, it regulates vascular tone, prevents clotting, and controls inflammation through nitric oxide and other signals. When impaired, vessels become rigid and inflamed, increasing blood pressure and cardiovascular risk. Dietary polyphenols including flavonoids like apigenin have been studied for their ability to support endothelial function ^[4], with one study specifically showing apigenin restored endothelial function and reversed aortic stiffness in aged mice ^[6].

Can I get enough apigenin from food, or do I need a supplement?

Chamomile tea, parsley, and celery are meaningful dietary sources of apigenin. Whether dietary intake is sufficient to replicate the effects seen in animal studies—where doses are often higher and more controlled—is unknown. Supplemental apigenin provides more predictable amounts, but no established cardiovascular dose has been validated in human trials. For most people, increasing intake of apigenin-rich foods is a reasonable, lower-risk starting point.

Does apigenin interact with blood pressure medications?

Yes, this is an important consideration. Apigenin inhibits CYP1A2, CYP2C9, and CYP3A4 enzymes in the liver, which metabolize many common medications including warfarin, certain statins, and some calcium channel blockers used to treat hypertension. This inhibition can raise blood levels of these drugs, potentially amplifying their effects or side effects. Anyone on prescription cardiovascular medications should consult their physician before using apigenin supplements.

Is apigenin safe to take with other supplements like melatonin or magnesium?

Apigenin binds benzodiazepine receptor sites on GABA-A receptors and has sedative properties. Combining it with other sedating supplements such as melatonin, valerian, or alcohol amplifies CNS depression risk and warrants caution. Combinations with non-sedating supplements like magnesium are generally considered lower risk, but interactions have not been systematically studied. When stacking supplements for cardiovascular health, discussing the full list with a healthcare provider is the prudent approach.

References

1. Olszanecki R et al. Flavonoids and nitric oxide synthase. Journal of physiology and pharmacology : an official journal of the Polish Physiological Society (2002). PMID 12512693
2. Chen CC et al. Calcium- and phosphatidylinositol 3-kinase/Akt-dependent activation of endothelial nitric oxide synthase by apigenin. Life sciences (2010). PMID 21034748
3. Simoncini T et al. Estrogen-like effects of wine extracts on nitric oxide synthesis in human endothelial cells. Maturitas (2011). PMID 21839593
4. Yamagata K et al. Dietary polyphenols regulate endothelial function and prevent cardiovascular disease. Nutrition (Burbank, Los Angeles County, Calif.) (2015). PMID 25466651
5. Ajebli M et al. Phytotherapy of Hypertension: An Updated Overview. Endocrine, metabolic & immune disorders drug targets (2020). PMID 31880255
6. Clayton ZS et al. Apigenin restores endothelial function by ameliorating oxidative stress, reverses aortic stiffening, and mitigates vascular inflammation with aging. American journal of physiology. Heart and circulatory physiology (2021). PMID 34114892
7. Cao Y et al. The antihypertensive potential of flavonoids from Chinese Herbal Medicine: A review. Pharmacological research (2021). PMID 34601080
8. Atucha NM et al. Effects of Flavonoids in Experimental Models of Arterial Hypertension. Current topics in medicinal chemistry (2022). PMID 34749613
9. Alobaidi S et al. Antihypertensive Property of Celery: A Narrative Review on Current Knowledge. International journal of food science (2024). PMID 38505582
10. Harahap U et al. Current insights and future perspectives of flavonoids: A promising antihypertensive approach. Phytotherapy research : PTR (2024). PMID 38616386
11. Klider LM et al. Nitric Oxide and Small and Intermediate Calcium-Activated Potassium Channels Mediate the Vasodilation Induced by Apigenin in the Resistance Vessels of Hypertensive Rats. Molecules (Basel, Switzerland) (2024). PMID 39598814
12. Tian J et al. Mitochondrial dysfunction in hypertension: mechanistic pathways and therapeutic implications. Functional & integrative genomics (2026). PMID 41656396

These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.